Halozyme Therapeutics, Inc. announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA®? [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE®? drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

HYQVIA®? was first granted FDA approval in 2014 for the treatment of primary immunodeficiency (PI) in adults, which has since been expanded to include children 2-16 years old. HYQVIA®?

is the only FDA-approved combination of immunoglobulin (IG) and hyaluronidase, which makes it a facilitated subcutaneous immunoglobulin (SCIG) infusion. For adults with CIDP, HYQVIA®? can be infused up to once monthly (every two, three or four weeks) due to ENHANZE®?), which facilitates the dispersion and absorption of large IG volumes in the subcutaneous space.

Because it is delivered subcutaneously, HYQVIA® can be administered by a healthcare professional in a medical office, infusion center or at a patient's home. In addition, it can be self-administered after appropriate patient or caregiver training.